K.J. Harrison & Partners Inc decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 91.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 526 shares of the biopharmaceutical company’s stock after selling 5,565 shares during the period. K.J. Harrison & Partners Inc’s holdings in Regeneron Pharmaceuticals were worth $406,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds have also modified their holdings of the stock. Insigneo Advisory Services LLC grew its stake in Regeneron Pharmaceuticals by 3.0% during the 4th quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock worth $343,000 after purchasing an additional 13 shares in the last quarter. Guardian Wealth Advisors LLC NC raised its position in Regeneron Pharmaceuticals by 3.3% in the 4th quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock valued at $342,000 after purchasing an additional 14 shares in the last quarter. TD Private Client Wealth LLC boosted its stake in shares of Regeneron Pharmaceuticals by 9.7% in the 4th quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 15 shares during the period. MCF Advisors LLC boosted its stake in shares of Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 15 shares during the period. Finally, Boyd Watterson Asset Management LLC OH grew its position in shares of Regeneron Pharmaceuticals by 1.4% during the first quarter. Boyd Watterson Asset Management LLC OH now owns 1,087 shares of the biopharmaceutical company’s stock worth $840,000 after buying an additional 15 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
REGN has been the topic of a number of recent research reports. Barclays cut their target price on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. Canaccord Genuity Group lowered their price target on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. BMO Capital Markets dropped their price objective on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a research report on Monday, May 18th. JPMorgan Chase & Co. reduced their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a report on Monday, May 18th. Finally, Morgan Stanley lifted their price objective on shares of Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the stock an “equal weight” rating in a research report on Friday, April 10th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $792.65.
Insider Activity at Regeneron Pharmaceuticals
In related news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, May 1st. The shares were sold at an average price of $705.24, for a total transaction of $70,524.00. Following the sale, the director directly owned 17,503 shares in the company, valued at $12,343,815.72. This trade represents a 0.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by company insiders.
Regeneron Pharmaceuticals Price Performance
REGN stock opened at $654.27 on Monday. The business has a 50 day moving average price of $652.48 and a 200 day moving average price of $725.31. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. The stock has a market cap of $69.17 billion, a price-to-earnings ratio of 15.94, a PEG ratio of 1.44 and a beta of 0.24. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $532.60 and a fifty-two week high of $821.11.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The company had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. During the same period in the prior year, the firm posted $8.22 earnings per share. The firm’s revenue was up 19.0% on a year-over-year basis. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.44 earnings per share for the current fiscal year.
Regeneron Pharmaceuticals Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were given a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.16%.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.
Read More
- Five stocks we like better than Regeneron Pharmaceuticals
- Visa’s Open USD Push Puts Circle’s Stablecoin Moat Under Pressure
- This Under-the-Radar Industrial Is Quietly Powering AI
- Why Microsoft Looks Like the Best Big Tech Trade for H2 2026
- Strategy’s Bitcoin Pivot Gives Investors a New Reason to Watch Preferred Shares
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
